BioNexus Gene Lab Corp. filings document material-event disclosures for its precision diagnostics strategy, subsidiary governance, capital structure, and periodic reporting obligations. Recent 8-K filings cover VitaGuard™ MRD commercialization activity, the Fidelion Diagnostics relationship, Chemrex governance restructuring, strategic partnership disclosures, and exhibits tied to company press releases and material agreements.
The company’s filing record also includes Form 12b-25 notifications for delayed periodic reports, with explanations tied to financial-reporting transitions and enhanced transaction review. Capital-structure disclosures include registration and equity financing arrangements, while governance disclosures address parent-level oversight, subsidiary board accountability, reporting protocols, and reporting-control processes.
BioNexus Gene Lab Corp (BGLC) is the issuer named in a Schedule 13G reporting 392,329 common shares, or 13.4%, beneficially owned by Fidelion Diagnostics Pte. Ltd., Molecule Bio LLC, Rainy Morning Technology (Hong Kong) Limited, and Ling Xiao. These reports concern the same shares held directly by Fidelion, rather than four separate blocks. Fidelion reports sole voting and dispositive power; the other reporting persons report shared voting and dispositive power.
The 13.4% calculation uses 2,933,442 BGLC shares outstanding as reflected in the company’s Form 10-Q for the quarter ended June 30, 2026. The reporting persons disclaim group status except for their respective pecuniary interests.
BioNexus Gene Lab Corp. (BGLC) signed a definitive agreement with Ruanyun Edai Technology Inc. for an exclusive Malaysian healthcare licence to CogniAI, with a 10-year term from closing and two five-year renewal options for BGLC. Exclusivity is subject to milestone, cure and termination provisions.
At closing, BGLC is to issue 410,000 common shares for the stated US$3.5 million licence consideration, described as a contractual amount and not a statement of fair value. BGLC is also to issue 150,000 common shares in exchange for 500,000 RYET ordinary shares, for 560,000 common shares in total. RYET's royalty is 10% of defined technology receipts actually collected; testing and clinical fees and separately identifiable services are excluded, and there is no minimum royalty or annual platform fee.
Closing and the share issuances remain pending. RYET must deliver the technology by December 4, 2026, after which BGLC plans acceptance testing; closing is subject to BGLC's written acceptance, satisfactory due diligence and required approvals. BGLC is targeting Malaysia's public healthcare digitalization program, which has a RM1 billion allocation covering 150 hospitals and more than 2,000 clinics, but has not been awarded a government contract; public-sector work depends on procurement.
BioNexus Gene Lab Corp reported that its Chief Executive Officer, President and director, Su‑Leng Tan Lee, beneficially owns 338,709 shares of Common Stock, representing approximately 11.5% of the outstanding shares as of August 13, 2026. These shares were granted on August 13, 2026 as a fully vested Other Stock-Based Award under the company’s 2025 Equity Incentive Plan as compensation for completed services, with no cash consideration and source-of-funds code “OO”. For plan valuation purposes only, the company used a fair-market value of $1.55 per share, corresponding to a total plan value of $524,998.95. Tan Lee holds sole voting and dispositive power over all 338,709 shares. The award was issued in an offshore transaction relying on Regulation S, includes a six‑month resale compliance period and related transfer restrictions, and does not obligate the company to register the shares for resale.
Tan Lee Su-Leng reported acquisition or exercise transactions in this Form 4 filing.
BioNexus Gene Lab Corp reported that Chief Executive Officer and director Tan Lee Su-Leng, a more than 10% shareholder, received a fully vested stock award. The award consists of 338,709 common shares with no par value, granted on August 13, 2026 under the company’s 2025 Equity Incentive Plan.
The shares were granted for completed services, with no cash consideration, and were valued for plan purposes at $1.55 per share, based on the Nasdaq closing price on August 12, 2026. Following this grant, the reporting person directly holds 338,709 common shares.
Yap Chee Keong reported acquisition or exercise transactions in this Form 4 filing.
BioNexus Gene Lab Corp director Yap Chee Keong received a fully vested stock award of 32,258 Common Shares on August 13, 2026. The award was granted for completed services under the 2025 Equity Incentive Plan, for no cash consideration, and is held as a direct ownership position of 32,258 shares. For plan purposes, the award was valued at $1.55 per share, equal to the Nasdaq closing price on August 12, 2026.
Bin Abdul Hamid Muhammad Azrul reported acquisition or exercise transactions in this Form 4 filing.
BioNexus Gene Lab Corp director Bin Abdul Hamid Muhammad Azrul received a fully vested stock award of 32,258 Common Shares on August 13, 2026. The award was granted under the company’s 2025 Equity Incentive Plan for completed services, for no cash consideration, and was valued for plan purposes at $1.55 per share, the Nasdaq closing price on August 12, 2026. Following this grant, his direct holdings total 32,258 shares.
Chong Set Fui reported acquisition or exercise transactions in this Form 4 filing.
BioNexus Gene Lab Corp’s Chief Financial Officer, Chong Set Fui, received a fully vested stock-based award of 96,774 common shares on August 13, 2026. The award was granted under the company’s 2025 Equity Incentive Plan for completed services, with no cash consideration, and was valued for plan purposes at $1.55 per share, the Nasdaq closing price on August 12, 2026. Following this grant, Chong Set Fui directly holds 96,774 common shares.
Low Jook Yuen reported acquisition or exercise transactions in this Form 4 filing.
BioNexus Gene Lab Corp director Low Jook Yuen received an equity compensation grant of 16,129 shares of common stock on August 13, 2026. The fully vested Other Stock-Based Award was granted for completed services under the company’s 2025 Equity Incentive Plan, for no cash consideration, and valued for plan purposes at $1.55 per share, the Nasdaq closing price on August 12, 2026. Following this award, Low Jook Yuen holds 17,390 shares of BioNexus Gene Lab Corp common stock directly.
BioNexus Gene Lab Corp. reported sharply lower activity for the six months ended June 30, 2026. Revenue fell to $98,998 from $4,397,328 a year earlier, almost entirely from its industrial chemicals segment, with genomic screening services contributing only $1,961. Gross profit was $12,192 and the company recorded a net loss of $830,026, improved from a loss of $1,239,499 in the prior-year period, helped by $178,691 of other income and tighter operating spending.
Total assets were $8,726,423, including cash and cash equivalents of $2,391,945 and investments in equity securities of $2,026,543. Current liabilities were $812,938, leaving positive working capital, and stockholders’ equity was $7,778,442. However, the company disclosed a substantial doubt about its ability to continue as a going concern, citing the cumulative deficit of $7,257,253, the $830,026 net loss, and $570,162 of operating cash outflows. Management believes existing cash and positive working capital can fund operations for at least twelve months, while noting it may seek additional financing that could include dilutive equity issuance or restrictive debt.